- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04660695
Nasobiliary Drain Assisted EUS-guided Gastroenterostomies in Unresectable Malignant Gastric Outlet Obstruction (PENGUIN)
Serie de Casos Prospectiva de Gastroenteroanastomosis Guiada Por Ecoendoscopia Para la obstrucción al Vaciado gástrico en Neoplasias Avanzadas Mediante la técnica Del Drenaje Nasobiliar
Gastric outlet obstruction in malignant disease appears when the tumor affects the gastroduodenal area, precluding the passage of food into the small bowel. This condition severely affects the quality of life. In patients with unresectable tumors, there are various available treatments:a surgical bypass connecting the stomach to the small bowel, placing a stent through the tumor to widen the passage and creating a gastrointestinal bypass with a lumen apposing metal stent. These stents are deployed with an echoendoscope, which allows to identify a small bowel loop and to deploy the stent, connecting the small bowel and the stomach. This is called a EUS-guided gastroenterostomy (EUS-GE).
EUS-GE is a rather novel procedure. Various techniques to create EUS-GE have been proposed. In this study, the investigators will retrieve data from the procedure and during the thirty following days from consecutive patients undergoing an EUS-GE. The objectives of the study are:
- To perform a detailed step by step description of the nasobiliary drain assisted EUS-GE
- To describe the adverse events encountered
- To describe the proportion of clinical and technical success
- To assess its impact on the patients' quality of life.
- To assess the evolution of the oral intake during the first month after the procedure
Study Overview
Status
Intervention / Treatment
Detailed Description
DESIGN
Prospective multicenter case series
AIMS
Primary aim To describe the proportions of technical and clinical success. To describe different variants in the nasobiliary drain assissted EUS-GE technique, offering a detailed step by step description of the procedure performance by different endoscopists
Secondary aims:
To describe the adverse encountered, their severity according to ASGE standards and their management.
To describe the time elapsed between the procedure and the initial oral intake.
To describe the evolution of the oral intake during the first month after the procedure To assess the impact of the operators experience on procedure times, adverse events and technical issues.
To assess the impact of the procedure on the quality of life of the participating patients.
STUDY POPULATION
All consecutive patients over 18 years of age receiving a nasobiliary drain assisted EUS-GE for unresectable malignant GOO are eligible to participate in this study. Patients with a previous gastroduodenal surgery, a previous endoscopic or surgical treatment for GOO, a simultaneous malignant biliary obstruction requiring endoscopic treatment, a distal bowel obstruction, ascites grade 2 or superior, uncorrectable coagulation disorders (INR>1,5) or severe thrombocytopenia (<50000 platelets/mm3). or unable to understand the questionnaires will be excluded.
INTERVENTION
At inclusion
Informed consent will be obtained. A clinical interview and a physical examination will be performed. TheEuropean Organization for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30), which includes 30 items covering a global health status scale, five functional scales and ten symptom scales will be assessed in a telephone interview.
Endoscopic procedure
All procedures will be performed under sedation. An assistant endoscopist or research nurse will retrieve all data regarding the procedure. Firstly, un upper digestive endoscopy is performed with a conventional gastroscope. A guidewire is passed through the malignant lesion causing the gastric outlet obstruction. Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum. At this point the gastroscope is substituted by a therapeutic echoendoscope. With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast. The echoendoscope is used to identify the target bowel loop. AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
Post procedure: Oral liquid intake can be restarted 4h after the procedure in patients presenting no signs or symptoms suggesting any adverse event. Pacients with an adequate tolerance might be discharged.
Follow-up
Clinical telephone interviews by an experienced research nurse will be held via telephone calls 1 day, 7 days and 30 days after the procedure. Oral intake and adverse events will be assessed every visit. Thirty days after the procedure a second evaluation of the EORTC-QLQ-C30 will be performed.
STATISTICAL ANALYSIS
Categorical variables were reported as percentages. Normally distributed continuous variables were reported as the mean with the standard deviation values. Non-normally distributed continuous variables were reported as the median and interquartile range. The EORTC QLQ-C30 descriptive analysis was performed with a specifically programmed Stata command (10). Variables regarding the procedure step by step analysis will only undergo a descriptive analysis. Differences between the different outcomes of the EORTC-QLQ-C30 will be assessed using linear mixed models with fixed effects for baseline values, and interaction with oncological treatment. The statistical analysis will be performed using the Stata package (StataCorp. 2013, College Station, Texas).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Vellore, India
- Christian Medical College
-
-
-
-
-
Alicante, Spain, 03010
- Hospital General Universitario de Alicante
-
Valladolid, Spain, 47014
- Hospital Universitario Río Hortega
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Complejo Hospitalario de Navarra
-
Pamplona, Navarra, Spain, 31008
- Clinica Universidad de Navarra
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All consecutive patients over 18 years of age submitted to any of the participanting center's endoscopy units to receive a nasobiliary drain assisted EUS-GE for unresectable malignant GOO are eligible to participate in this study.
Patients with a previous gastroduodenal surgery, a previous endoscopic or surgical treatment for GOO, a simultaneous malignant biliary obstruction or unable to understand the questionnaires will be excluded.
Description
Inclusion Criteria:
- Patients over 18 years of age
- unresectable malignant gastric outlet obstruction
- Undergoing placement of nasobiliary drain assisted EUS-GE
Exclusion Criteria:
- Previous gastroduodenal surgery
- Previous endoscopic or surgical treatment for gastric outlet obstruction
- Simultaneous biliary obstruction (malignant or benign) requiring endoscopic treatment
- Simultaneous upper digestive tract disease requiring endoscopic treatment in the same procedure
- Unable to understand the questionnaires
- Distal bowel obstruction
- Ascites grade 2 or superior
- Uncorrectable coagulation disorders (INR>1,5) or severe thrombocytopenia (<50000 platelets/mm3).
- Active, symptomatic SARS-CoV-2 infection
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1
Patients included will undergo an EUS-guided gastroenterostomy with a 15x10mm or a 20x10mm lumen apposing metal Stent (Axios, Boston Scientific, Mass).
|
Firstly, un upper digestive endoscopy is performed with a conventional gastroscope.
A guidewire is passed through the malignant lesion causing the gastric outlet obstruction.
Once the guidewire is located in the distal duodenum/proximal jejunum, a nasobiliary drain (Nasal Biliary Drainage Sets, Cook medical, Indiana) is advanced over the guidewire until its distal end is placed in the distal duodenum/jejunum.
At this point the gastroscope is substituted by a therapeutic echoendoscope.
With the echoendoscope in place, the target bowel loop is filled with saline combined with methilene blue and radiopaque contrast.
The echoendoscope is used to identify the target bowel loop.
AFter identifying the target, a lumen apposing metal stent (Axios, Boston Scientific, Massachusetts) is deployed across the gastric and bowel using its electrocautery enhanced deployment device.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: Day +1
|
An adequate stent placement across the GI walls, with one flange in the gastric cavity and the other in the small bowel lumen.
It has to be confirmed either fluoroscopically or endoscopically.
|
Day +1
|
Early Clinical Success
Time Frame: Day +7
|
Defined as a GOOSS >=2.
|
Day +7
|
Clinical Success
Time Frame: Day +30
|
Defined as a GOOSS >=2.
|
Day +30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Gastric outlet obstruction score system (GOOSS)
Time Frame: Baseline
|
The GOOSS is a previously defined classification of Gastric outlet obstruction which incudes 4 categories (0-Nil Per Os; 1 liquids only; 2 soft diet; 3 low residue or full diet)
|
Baseline
|
Early Gastric outlet obstruction score system (GOOSS)
Time Frame: day +7
|
The GOOSS is a previously defined classification of Gastric outlet obstruction which incudes 4 categories (0-Nil Per Os; 1 liquids only; 2 soft diet; 3 low residue or full diet)
|
day +7
|
Final Gastric outlet obstruction score system (GOOSS)
Time Frame: day +30
|
The GOOSS is a previously defined classification of Gastric outlet obstruction which incudes 4 categories (0-Nil Per Os; 1 liquids only; 2 soft diet; 3 low residue or full diet)
|
day +30
|
Baseline European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30)
Time Frame: Baseline
|
The EORTC-QLQ-C30 is a validated questionnaire (with validated translations in Spanish), which includes 30 items covering a global health status scale, five functional scales and ten symptom scales
|
Baseline
|
Final European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30)
Time Frame: Baseline, day+30
|
The EORTC-QLQ-C30 is a validated questionnaire (with validated translations in Spanish), which includes 30 items covering a global health status scale, five functional scales and ten symptom scales
|
Baseline, day+30
|
Number of Participants With intraprocedure Treatment-Related Adverse Events as Assessed by the ASGE classification
Time Frame: day+1,
|
The ASGE classification is a tool developed to describe and assess the severity of endoscopy related adverse events.
|
day+1,
|
Number of Participants With Early Treatment-Related Adverse Events as Assessed by the ASGE classification
Time Frame: day+7
|
The ASGE classification is a tool developed to describe and assess the severity of endoscopy related adverse events.
|
day+7
|
Number of Participants With Delayed Treatment-Related Adverse Events as Assessed by the ASGE classification
Time Frame: day+30
|
The ASGE classification is a tool developed to describe and assess the severity of endoscopy related adverse events.
|
day+30
|
Recurrent GOO
Time Frame: Day +30
|
In patients achieving clinical success in day +7, recurrent GOO is defined as the development of nausea and vomiting and/or a GOOSS<2.
|
Day +30
|
Target bowel loop diameter (mm)
Time Frame: Procedure
|
Diameter measured with the EUS of the dilated bowel loop.
It should be measured just before placing the stent
|
Procedure
|
Total volume infused (ml)
Time Frame: Procedure
|
Volume of saline, methilene blue solution or radiopaque contrast solution instiled to dilate the target bowel loop
|
Procedure
|
Number of patients undergoing balloon dilation
Time Frame: Procedure
|
After deploying the stent, it might be dilated with a controlled radial expansion balloon dilator
|
Procedure
|
Type of fluid employed
Time Frame: Procedure
|
Three different fluids can be used to dilate the target bowel loop, saline, methilene blue diluted in saline or radiopaque contrast diluted in saline
|
Procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Carlos de la Serna Higuera, MD, Hospital del Rio Hortega
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI152-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on EUS-guided gastroenterostomy
-
Universitaire Ziekenhuizen KU LeuvenFondazione Policlinico Universitario Agostino Gemelli IRCCS; Universita di... and other collaboratorsNot yet recruitingGastric Outlet Obstruction
-
National Taiwan University HospitalNot yet recruitingMalignant Gastric Outlet Obstruction
-
Coordinación de Investigación en Salud, MexicoRecruitingMalignant Gastric Outlet ObstructionMexico
-
Weill Medical College of Cornell UniversityUnknownPancreatic Cancer | Cholangiocarcinoma | Bile Duct Cancer | Chronic Pancreatitis | Biliary Stricture | Biliary Obstruction | Ampullary Cancer | Stent Obstruction | Proximal Duct Stricture | Distal Duct Stricture | Biliary Sphincter Stenosis | Impacted Stones | Peri-ampullary Diverticula | Altered AnatomyUnited States, Brazil
-
H. Lee Moffitt Cancer Center and Research InstituteAmerican Cancer Society, Inc.TerminatedEvaluation of Image-guided Brushing of Pancreatic Cyst Wall in Diagnosis of Cystic Pancreatic TumorsPancreatic TumorsUnited States
-
Samsung Medical CenterCompletedTumor Appearance of Biliary System ObstructionKorea, Republic of
-
Chinese University of Hong KongRecruiting
-
Chinese University of Hong KongSoonChunHyang University School of MedicineCompletedAcute Cholecystitis | Pancreatic Pseudocyst | Biliary Obstruction | Pancreatic NecrosisChina
-
Hospital Universitario Virgen MacarenaDelos ClinicalUnknownMalignant Ascites
-
Centro Hospitalar De São João, E.P.E.UnknownPancreatic Neoplasm | Biopsy, Fine-Needle | EndosonographyPortugal